FDA Approves Orzeyful, First Narcolepsy Type 1 Drug

The U.S. Food and Drug Administration approved Orzeyful (oveporexton) tablets on Thursday for the treatment of narcolepsy type 1 in adults. The new drug is the first medication authorized to address the full spectrum of symptoms associated with this condition, including excessive daytime sleepiness, cataplexy, and disrupted nighttime sleep.

Orzeyful represents a breakthrough because it directly targets the underlying loss of orexin signaling that causes narcolepsy type 1. By restoring this critical neuropeptide pathway, the drug offers a mechanism‑based approach rather than merely managing individual symptoms. The approval follows clinical trials demonstrating significant improvements in wakefulness and reductions in cataplexy episodes compared with placebo.

The availability of Orzeyful may change the therapeutic landscape for narcolepsy type 1, providing patients with a first‑in‑class option that addresses the root cause of the disease. Further post‑marketing studies will monitor long‑term safety and effectiveness as the medication enters broader clinical use.